DCPH Stock Ownership Activity
DECIPHERA PHARMACEUTICALS IN 13F holders
No value investing guru has made any change to the DECIPHERA PHARMACEUTICALS IN (DCPH) position according to the gurus' latest SEC quarterly report(s).
Which gurus or hedge funds are buying DCPH now?
According to the latest SEC filing(s) DECIPHERA PHARMACEUTICALS IN (DCPH) has not been purchased by any super investor.
To see more about who is investing in DECIPHERA PHARMACEUTICALS IN (DCPH), please go to the DCPH ownership page.
2018 Q4
(1 result)
Current price: $25.59
33.91%
Reported price*: $38.72
2018 Q3
(1 result)
Current price: $25.59
33.91%
Reported price*: $38.72
2018 Q2
(1 result)
Current price: $25.59
34.97%
Reported price*: $39.35
2018 Q1
(1 result)
Current price: $25.59
27.70%
Reported price*: $20.04
2017 Q4
(1 result)
Current price: $25.59
12.88%
Reported price*: $22.67
2017 Q3
(1 result)
Current price: $25.59
34.76%
Reported price*: $18.99
6 of 6
Shares, change to shares, sold shares - split-adjusted.
Reported price - this doesn't represent the actual buy or sell price.
It is the split-adjusted price of the security as of the last day of the reported period.
Value or Price - If the security is completely sold out, we show the reported value (or price) prior to the actual period.